Related Experiment Videos
Chronic rejection and chronic cyclosporin toxicity in renal allografts
M Pascual1, R D Swinford, J R Ingelfinger
1Renal Unit and Transplantation Unit, Massachusetts General Hospital, Boston, USA. mpascual@partners.org
Abstract:
Recent evidence indicates that growth factors are critically important in both chronic rejection and chronic cyclosporin A toxicity, suggesting that these two entities share a common pathophysiological pathway, leading to progressive allograft failure. Here, Manuel Pascual and colleagues discuss the relevance of growth factors to chronic allograft nephropathy, and the implications for therapy in view of the great choice of immunosuppressive drugs now available.
Insights
Growth factors play a key role in chronic allograft nephropathy, linking chronic rejection and cyclosporin A toxicity. Understanding this pathway offers new therapeutic strategies for kidney transplant patients.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Chronic rejection and cyclosporin A toxicity are major causes of allograft failure.
- Both conditions appear to share a common underlying pathophysiological pathway.
- Growth factors are increasingly recognized as critical mediators in these processes.
Purpose of the Study:
- To discuss the role of growth factors in chronic allograft nephropathy.
- To explore the therapeutic implications of growth factor involvement.
- To consider the impact of available immunosuppressive drugs on these pathways.
Main Methods:
- Review of recent evidence on growth factors in transplantation.
- Analysis of the pathophysiological links between chronic rejection and cyclosporin A toxicity.
- Discussion of therapeutic strategies based on growth factor modulation.
Main Results:
- Growth factors are critically important in both chronic rejection and chronic cyclosporin A toxicity.
- These conditions share a common pathophysiological pathway leading to progressive allograft failure.
- Targeting growth factors may offer novel therapeutic avenues.
Conclusions:
- Growth factors are central to the development of chronic allograft nephropathy.
- Therapeutic strategies should consider the modulation of growth factors.
- The choice of immunosuppressive drugs has implications for managing these pathways.